Sangamo Therapeutics, Inc
isaralgagene civaparvovec
Fabry disease
Resolved
7days ago
FDA decision · Jun 30, 2026
What's at stake
The FDA's approval decision on isaralgagene civaparvovec for Fabry disease is due Jun 30, 2026. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 8-K
verified 17h ago
“Sangamo is advancing the Chemistry, Manufacturing and Controls (CMC) module, ahead of completion of the rolling BLA submission for isaralgagene civaparvovec, expected as early as the summer of 2026, subject to the ability to secure adequate”